A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Gemcitabine; XL 844
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Exelixis
  • Most Recent Events

    • 04 Oct 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top